**Massive Bio Receives CNIL Certification for GDPR Compliance** Boca Raton, Florida — Massive Bio, a leading technology company specializing in oncology research and treatment, has recently received certification from the French National Data Protection Commission (CNIL). This certification confirms that Massive Bio’s cloud-based platform complies with the General Data Protection Regulation (GDPR) and French health data protection laws. The achievement is a significant milestone for the company, enabling it to securely process medical records of French patients and marking a crucial step in its expansion into the European market. CNIL, one of the most stringent regulatory bodies in the European Union, conducted rigorous reviews and tests to ensure Massive Bio's platform met high standards of data security and privacy. The certification is particularly important for the French healthcare system, which is seeing increased investment in artificial intelligence (AI) to enhance its efficiency and quality. By providing a secure and reliable data management solution, Massive Bio's platform can support various medical research and clinical trials, further accelerating the adoption of AI in healthcare. CEO of Massive Bio, Melissa Jones, expressed her satisfaction with the certification: "We are honored to receive CNIL's certification, which is a testament to our commitment to data protection and privacy. We will continue to offer safe, efficient, and transparent medical services, ensuring that patients and doctors trust our platform." Massive Bio’s cloud platform is designed to manage patient information securely, supporting personalized treatment plans and streamlining the recruitment process for clinical trials. The platform’s advanced capabilities align with France’s digital healthcare initiatives, which aim to create a more efficient and patient-centric healthcare system. This certification not only opens the door to the French market but also sets a strong foundation for expansion into other EU countries. The importance of data security in the healthcare industry, especially in the era of rapidly advancing technology, cannot be overstated. Massive Bio’s certification enhances its credibility and positions it as a leader in medical data management. The company has already established partnerships with healthcare providers in several countries, demonstrating its potential for global impact. With this new certification, Massive Bio is poised for significant growth in the coming years. **Quantum Knight Achieves FDA Approval for CLEAR™ Encryption System** Palo Alto, California — Quantum Knight, an innovative leader in quantum-safe encryption and cybersecurity, announced in February that its flagship encryption system, CLEAR™ (Corporate Layer for Enterprise Resilience and Access), has received authorization from the U.S. Food and Drug Administration (FDA). This marks the first time an independent encryption solution has been approved for use in life-critical medical and digital infrastructure, highlighting a major breakthrough in the field of quantum security. The FDA’s approval process is known for its rigor, involving multiple rounds of testing to ensure both the safety and effectiveness of the technology. CLEAR™ has successfully passed all these tests over the past year, demonstrating its capability to protect patient data and medical devices from potential attacks and threats. This certification not only recognizes the technological advancements of CLEAR™ but also paves the way for practical applications of quantum security in the broader medical field. David Park, Quantum Knight’s co-founder and Chief Technology Officer, emphasized the company’s goal of creating a future-proof encryption system: "Our objective is to develop a security framework that remains robust even in the face of emerging quantum computing threats. CLEAR™ utilizes advanced quantum key distribution technology to generate and distribute keys dynamically during data transmission, ensuring the highest level of security." The system’s flexibility and scalability are additional strengths, allowing it to integrate seamlessly with existing medical devices and information systems without requiring significant changes to current security architectures. This is particularly valuable as the medical industry grapples with the increasing reliance on internet-connected devices and the evolving landscape of cybersecurity threats. Quantum Knight plans to deploy CLEAR™ to major medical device manufacturers and large hospitals in the United States over the next few months. The company is also working with regulatory bodies in other countries to secure international certifications, further expanding its reach and impact. Industry insiders have hailed Quantum Knight’s achievement as a pivotal moment in the transition from theoretical quantum security to practical implementation. Sarah Turner, a medical cybersecurity expert, commented, “The FDA approval of CLEAR™ is not only a significant win for Quantum Knight but also a crucial step for the entire industry toward a more secure future. Protecting patient privacy and enhancing the safety of medical systems are paramount.” James Fletcher, a professor of quantum information science at Cornell University, added, “This is a significant development that showcases the potential of quantum technology to solve real-world problems. Quantum Knight’s success underscores the real-world value and feasibility of quantum security solutions in commercial settings.” Quantum security advancements offer new hope for the healthcare industry and present viable solutions for other highly sensitive sectors. Quantum Knight, founded in 2015 and backed by prominent venture capital firms, has emerged as a leader in quantum-safe encryption, driving technological progress and supporting digital transformation across various industries. The certifications and approvals awarded to both Massive Bio and Quantum Knight highlight the companies' commitment to high standards of data protection and innovation. These achievements not only enhance their market positions but also contribute to building more trustworthy and secure digital healthcare ecosystems. As the demand for data security continues to grow, the success of these companies sets a benchmark for the future of healthcare technology and operations.